Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,409
  • Shares Outstanding, K 74,955
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,550 K
  • 60-Month Beta 1.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.28
Trade CTXR with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 0.03
  • Number of Estimates 2
  • High Estimate 0.16
  • Low Estimate -0.09
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +123.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2000 +60.00%
on 02/05/21
2.9000 -33.79%
on 02/22/21
+0.4800 (+33.33%)
since 02/03/21
3-Month
0.9701 +97.92%
on 12/31/20
2.9000 -33.79%
on 02/22/21
+0.7900 (+69.91%)
since 12/03/20
52-Week
0.4150 +362.65%
on 03/19/20
2.9000 -33.79%
on 02/22/21
+1.2300 (+178.26%)
since 03/03/20

Most Recent Stories

More News
Thinking about buying stock in BlackBerry, Express, Norwegian Cruise Line, Citius Pharmaceuticals, or Verizon?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BB, EXPR, NCLH, CTXR, and VZ.

CTXR : 1.9200 (-4.95%)
BB : 10.15 (-3.33%)
EXPR : 2.55 (-3.77%)
NCLH : 33.13 (+6.25%)
VZ : 55.38 (+0.73%)
Thinking about buying stock in Workhorse Group, Globalstar, Palantir Technologies, Marathon Oil, or Citius Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WKHS, GSAT, PLTR, MRO, and CTXR.

GSAT : 1.5500 (-8.28%)
CTXR : 1.9200 (-4.95%)
WKHS : 14.92 (-7.50%)
MRO : 11.63 (+3.56%)
PLTR : 23.59 (-3.64%)
Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Cancer

PALM BEACH,  Fla., /PRNewswire/ -- In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue...

ONCY : 3.24 (+2.21%)
ONC.TO : 4.07 (+1.50%)
VCNX : 3.36 (-3.72%)
PDSB : 3.82 (-9.05%)
CTXR : 1.9200 (-4.95%)
CLVS : 5.55 (-2.97%)
Thinking about buying stock in Celsion Corp, Can Fite Biopharma, ConforMIS Inc, Citius Pharmaceuticals, or Vuzix Corp?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLSN, CANF, CFMS, CTXR, and VUZI.

CANF : 1.9500 (-2.99%)
CFMS : 1.0900 (-8.40%)
CLSN : 2.04 (-4.67%)
CTXR : 1.9200 (-4.95%)
VUZI : 20.26 (-10.83%)
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

, /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today...

CTXR : 1.9200 (-4.95%)
Thinking about buying stock in Energous Corp, Casa Systems, Citius Pharmaceuticals, Creative Realities, or Precision BioSciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WATT, CASA, CTXR, CREX, and DTIL.

CASA : 7.93 (-1.12%)
CREX : 2.85 (+5.95%)
DTIL : 11.36 (-7.64%)
CTXR : 1.9200 (-4.95%)
WATT : 4.21 (-9.46%)
Thinking about buying stock in Sundial Growers, AMC Entertainment, Northern Dynasty Minerals, Citius Pharmaceuticals, or Hepion Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, AMC, NAK, CTXR, and HEPA.

NAK : 0.7187 (-3.05%)
HEPA : 2.02 (-2.42%)
SNDL : 1.3000 (-5.80%)
CTXR : 1.9200 (-4.95%)
AMC : 8.58 (-3.92%)
Thinking about buying stock in Diffusion Pharmaceuticals, Northern Dynasty Minerals, Zomedica, Sundial Growers, or Citius Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DFFN, NAK, ZOM, SNDL, and CTXR.

NAK : 0.7187 (-3.05%)
ZOM : 2.03 (-4.25%)
SNDL : 1.3000 (-5.80%)
CTXR : 1.9200 (-4.95%)
DFFN : 1.0200 (-3.77%)
Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

, /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today...

CTXR : 1.9200 (-4.95%)
Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021

, /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today issued...

CTXR : 1.9200 (-4.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 2.1000
2nd Resistance Point 2.0600
1st Resistance Point 1.9900
Last Price 1.9200
1st Support Level 1.8800
2nd Support Level 1.8400
3rd Support Level 1.7700

See More

52-Week High 2.9000
Fibonacci 61.8% 1.9507
Last Price 1.9200
Fibonacci 50% 1.6575
Fibonacci 38.2% 1.3643
52-Week Low 0.4150

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar